A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer

Status:

Opening Soon

Phase

Neoadjuvant

Line of Therapy

Early Cancer

Disease Stage

Biomarker(s)

ER+, HER2-

Investigational

Product

Nivolumab, Palbociclib & Anastrozole

Treatment Arms

oNivolumab+Palbociclib+Anastrozole

o Palbociclib+ANZ then Nivolumab+Palbociclib+ANZ

o Palbociclib+ANZ